 |
0 Diseases |  |
137 Trials |
|
137 Trials |  |
5343 News |  |
| «12...7879808182838485868788...9091» |
- | tetracycline / Generic mfg.
Enrollment open: Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin (clinicaltrials.gov) - Feb 10, 2020
P4, N=250, Recruiting, Sponsor: Shandong University
Not yet recruiting --> Recruiting
- | Lamprene (clofazimine) / Novartis, Sirturo (bedaquiline) / J&J, Pharmstandard, NN1213 / Novo Nordisk
Enrollment closed, Trial primary completion date: STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (clinicaltrials.gov) - Feb 5, 2020
P3, N=588, Active, not recruiting, Sponsor: IUATLD, Inc
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2021 --> Jul 2021
- | piperacillin sodium/tazobactam sodium / Generic mfg., levofloxacin / Generic mfg.
New P4 trial, Biopsy: Characterization of lung concentrations of the antibiotics piperacillin/tazobactam and levofloxacin (EUDRACT) - Feb 4, 2020
P4, N=18, Ongoing, Sponsor: Medical University of Vienna
- | levofloxacin / Generic mfg.
Trial completion date, Trial primary completion date: Short Compared With Standard Duration of Antibiotic Treatment for AECOPD (clinicaltrials.gov) - Jan 30, 2020
P2, N=520, Recruiting, Sponsor: University of Monastir
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2021 --> Jul 2021 Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2021
- | levofloxacin / Generic mfg.
Enrollment change, Trial withdrawal: TriDoRe: Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More (clinicaltrials.gov) - Jan 21, 2020
P3, N=0, Withdrawn, Sponsor: Institute of Tropical Medicine, Belgium
Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2021 N=3000 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment closed: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Jan 14, 2020
P4, N=1786, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=3000 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- || levofloxacin / Generic mfg., prulifloxacin / Generic mfg.
Enrollment closed: Prulifloxacin in Chronic Bacterial Prostatitis (CBP) (clinicaltrials.gov) - Jan 8, 2020
P2, N=148, Active, not recruiting, Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | levofloxacin / Generic mfg., fluconazole oral / Generic mfg., acyclovir / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, IO biomarker: ZENITH: Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies (clinicaltrials.gov) - Jan 7, 2020
P2, N=20, Completed, Sponsor: Azienda Ospedaliero, Universitaria Pisana
Recruiting --> Active, not recruiting Suspended --> Completed | N=50 --> 20 | Trial completion date: Jan 2021 --> Sep 2019 | Trial primary completion date: Jan 2019 --> Sep 2019
- | Trial completion date, Trial primary completion date: Topical Antibiotics in Chronic Rhinosinusitis (clinicaltrials.gov) - Jan 3, 2020
P1/2, N=40, Recruiting, Sponsor: Mayo Clinic
Suspended --> Completed | N=50 --> 20 | Trial completion date: Jan 2021 --> Sep 2019 | Trial primary completion date: Jan 2019 --> Sep 2019 Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- |||| levofloxacin / Generic mfg.
New P1/2 trial: The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% (clinicaltrials.gov) - Jan 2, 2020
P1/2, N=128, Recruiting, Sponsor: National University of Malaysia
- | levofloxacin / Generic mfg., acyclovir / Generic mfg.
New trial: ABSOSASAPOIK: Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis (clinicaltrials.gov) - Dec 29, 2019
P, N=145, Completed, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- | levofloxacin / Generic mfg.
New trial: Prophylaxis001: Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) (clinicaltrials.gov) - Dec 26, 2019
P=N/A, N=1350, Completed, Sponsor: Jessa Hospital
- |||| levofloxacin / Generic mfg.
New P1/2 trial: The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% (clinicaltrials.gov) - Dec 26, 2019
P1/2, N=128, Recruiting, Sponsor: National University of Malaysia
- |||| levofloxacin / Generic mfg., cefuroxime / Generic mfg.
New P1/2 trial: Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime (clinicaltrials.gov) - Dec 25, 2019
P1/2, N=138, Recruiting, Sponsor: National University of Malaysia
- | levofloxacin / Generic mfg.
New P4 trial: Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer (clinicaltrials.gov) - Dec 18, 2019
P4, N=144, Recruiting, Sponsor: Shanxi Zhendong Pharmacy Co., Ltd
- | NN1213 / Novo Nordisk
Enrollment closed, Enrollment change: Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations (clinicaltrials.gov) - Dec 11, 2019
P3, N=33, Active, not recruiting, Sponsor: University of Rochester
Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Recruiting --> Active, not recruiting | N=70 --> 33
- | Trial completion, Trial completion date, Trial primary completion date: Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy (clinicaltrials.gov) - Dec 10, 2019
P4, N=112, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting --> Active, not recruiting | N=70 --> 33 Recruiting --> Completed | Trial completion date: Mar 2019 --> Sep 2019 | Trial primary completion date: Jan 2019 --> Sep 2019
- | levofloxacin / Generic mfg., fosfomycin tromethamine / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS) (clinicaltrials.gov) - Nov 21, 2019
P4, N=62, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial completion date: Mar 2019 --> Sep 2019 | Trial primary completion date: Jan 2019 --> Sep 2019 N=634 --> 62 | Trial completion date: Jan 2021 --> Oct 2019 | Recruiting --> Terminated | Trial primary completion date: Jan 2021 --> Oct 2019; inadequate enrollment.
- | Sufenta (sufentanil) / Akorn
Trial completion, Trial completion date, Trial primary completion date: Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO) (clinicaltrials.gov) - Nov 15, 2019
P=N/A, N=56, Completed, Sponsor: Yonsei University
N=634 --> 62 | Trial completion date: Jan 2021 --> Oct 2019 | Recruiting --> Terminated | Trial primary completion date: Jan 2021 --> Oct 2019; inadequate enrollment. Recruiting --> Completed | Trial completion date: Dec 2019 --> Jan 2019 | Trial primary completion date: Dec 2019 --> Jan 2019
- | levofloxacin / Generic mfg., amikacin sulfate / Generic mfg.
Enrollment change, Trial initiation date: TB-TRUST: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) (clinicaltrials.gov) - Nov 15, 2019
P=N/A, N=354, Not yet recruiting, Sponsor: Huashan Hospital
Recruiting --> Completed | Trial completion date: Dec 2019 --> Jan 2019 | Trial primary completion date: Dec 2019 --> Jan 2019 N=220 --> 354 | Initiation date: May 2019 --> Dec 2019
- |||| Nuzyra (omadacycline) / Paratek
Trial completion: IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis (clinicaltrials.gov) - Nov 11, 2019
P2, N=201, Completed, Sponsor: Paratek Pharmaceuticals Inc
N=220 --> 354 | Initiation date: May 2019 --> Dec 2019 Recruiting --> Completed
- | gentamicin sulfate / Generic mfg.
Enrollment change, Combination therapy: Efficacy and Safety of Garamycin (clinicaltrials.gov) - Nov 10, 2019
P4, N=88, Completed, Sponsor: University Hospital, Geneva
Recruiting --> Completed N=144 --> 88
- || ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg.
Trial completion: PRO-174/I: Safety and Tolerability of the PRO-174 Versus Sophix (clinicaltrials.gov) - Oct 31, 2019
P1, N=30, Completed, Sponsor: Laboratorios Sophia S.A de C.V.
N=144 --> 88 Recruiting --> Completed
- | PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial primary completion date, Pneumococcal vaccines: Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents (clinicaltrials.gov) - Oct 22, 2019
P4, N=40, Enrolling by invitation, Sponsor: Minsk State Clinical Hospital No 9
Recruiting --> Completed Trial primary completion date: Aug 2019 --> Dec 2019
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Kineret (anakinra) / SOBI
Trial completion date, Trial primary completion date: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants (clinicaltrials.gov) - Oct 22, 2019
P=N/A, N=500, Recruiting, Sponsor: Duke University
Trial primary completion date: Aug 2019 --> Dec 2019 Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2019 --> Sep 2020
- | levofloxacin / Generic mfg.
Trial completion date, Trial primary completion date: PERFECT: Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients (clinicaltrials.gov) - Oct 10, 2019
P=N/A, N=360, Recruiting, Sponsor: University Medical Center Groningen
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2019 --> Sep 2020 Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Nov 2018 --> Nov 2020
- | tetracycline / Generic mfg.
New P4 trial: Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin (clinicaltrials.gov) - Oct 9, 2019
P4, N=250, Not yet recruiting, Sponsor: Shandong University
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy (clinicaltrials.gov) - Oct 1, 2019
P1, N=150, Recruiting, Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Nov 2018 --> Nov 2020 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | New P3 trial: THD-HP: Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection. (clinicaltrials.gov) - Sep 26, 2019
P3, N=362, Not yet recruiting, Sponsor: University of Bari
- | Mycobutin (rifabutin) / Pfizer, Lupin
New P4 trial: Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication. (clinicaltrials.gov) - Sep 15, 2019
P4, N=304, Recruiting, Sponsor: Konstantopoulio-Patission General Hospital of Nea Ionia
- | Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Enrollment closed: TEDIZOAM: Tedizolid Prolonged Treatment for Prosthetic Joint Infections (clinicaltrials.gov) - Sep 11, 2019
P=N/A, N=35, Active, not recruiting, Sponsor: Tourcoing Hospital
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Recruiting --> Active, not recruiting
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus (clinicaltrials.gov) - Sep 4, 2019
P3, N=324, Recruiting, Sponsor: University Hospital, Tours
Recruiting --> Active, not recruiting Trial completion date: Oct 2019 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2021
- | Enrollment open: Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care (clinicaltrials.gov) - Aug 29, 2019
P3, N=400, Recruiting, Sponsor: Wits Health Consortium (Pty) Ltd
Trial completion date: Oct 2019 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2021 Not yet recruiting --> Recruiting
- | murepavadin (POL7080) / Spexis
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: PRISM-MDR: Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa (clinicaltrials.gov) - Aug 28, 2019
P3, N=41, Terminated, Sponsor: Polyphor Ltd.
Not yet recruiting --> Recruiting N=150 --> 41 | Trial completion date: Jul 2020 --> Jul 2019 | Suspended --> Terminated | Trial primary completion date: May 2020 --> Jul 2019; Safety data review
- | New P3 trial: Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care (clinicaltrials.gov) - Aug 19, 2019
P3, N=400, Not yet recruiting, Sponsor: Wits Health Consortium (Pty) Ltd
- | levofloxacin / Generic mfg., clarithromycin / Generic mfg.
New trial: HP: Tailored Juice-guided Eradication Therapy (clinicaltrials.gov) - Aug 19, 2019
P=N/A, N=182, Completed, Sponsor: Kaohsiung Medical University
- | Sirturo (bedaquiline) / J&J, Pharmstandard, NN1213 / Novo Nordisk
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis (clinicaltrials.gov) - Aug 19, 2019
P2/3, N=154, Active, not recruiting, Sponsor: University of Cape Town
N=150 --> 41 | Trial completion date: Jul 2020 --> Jul 2019 | Suspended --> Terminated | Trial primary completion date: May 2020 --> Jul 2019; Safety data review Recruiting --> Active, not recruiting | N=300 --> 154 | Trial completion date: Jan 2019 --> Dec 2020 | Trial primary completion date: Jan 2019 --> Dec 2020
- | Trial completion date, Trial primary completion date: Topical Antibiotics in Chronic Rhinosinusitis (clinicaltrials.gov) - Aug 14, 2019
P1/2, N=40, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=300 --> 154 | Trial completion date: Jan 2019 --> Dec 2020 | Trial primary completion date: Jan 2019 --> Dec 2020 Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Dec 2019
- | levofloxacin / Generic mfg., rifampicin / Generic mfg.
Trial completion date, Trial primary completion date: TBM-KIDS: Optimizing Treatment to Improve TBM Outcomes in Children (clinicaltrials.gov) - Aug 8, 2019
P1/2, N=120, Recruiting, Sponsor: Johns Hopkins University
Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Dec 2019 Trial completion date: Jun 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> Sep 2020
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: BISER-2: Sputum Microbiota and the Association With Clinical Parameters in Steady-state, Acute Exacerbation and Convalescence of Bronchiectasis (clinicaltrials.gov) - Aug 1, 2019
P=N/A, N=120, Recruiting, Sponsor: Guangzhou Institute of Respiratory Disease
Trial completion date: Jun 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> Sep 2020 Trial completion date: Dec 2017 --> Dec 2023 | Trial primary completion date: Nov 2017 --> Dec 2023
- | levofloxacin / Generic mfg.
New P4 trial: Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt (clinicaltrials.gov) - Jul 30, 2019
P4, N=330, Completed, Sponsor: Ayman Magd Eldin Mohammad Sadek
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Head-to-Head: ENVELOPE: Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. (clinicaltrials.gov) - Jul 29, 2019
P3, N=1492, Recruiting, Sponsor: Vanderbilt University Medical Center
Trial completion date: Dec 2017 --> Dec 2023 | Trial primary completion date: Nov 2017 --> Dec 2023 Trial completion date: Jun 2019 --> Aug 2020 | Trial primary completion date: Jun 2019 --> Jul 2020
- | levofloxacin / Generic mfg.
New P4 trial: A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation) (clinicaltrials.gov) - Jul 28, 2019
P4, N=240, Not yet recruiting, Sponsor: China Academy of Chinese Medical Sciences
- | levofloxacin / Generic mfg.
New P4 trial: A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome) (clinicaltrials.gov) - Jul 23, 2019
P4, N=184, Not yet recruiting, Sponsor: China Academy of Chinese Medical Sciences
- | AzaSite (1% azithromycin ophthalmic solution) / Sun Pharma, Akorn, Nicox
Trial completion date, Trial primary completion date: Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - Jul 15, 2019
P=N/A, N=20, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Jun 2019 --> Aug 2020 | Trial primary completion date: Jun 2019 --> Jul 2020 Trial completion date: Sep 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
- | NN1213 / Novo Nordisk
Trial completion: Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis (clinicaltrials.gov) - Jun 17, 2019
P2, N=97, Completed, Sponsor: Vanderbilt University
Trial completion date: Sep 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019 Recruiting --> Completed
- ||||||| tobramycin/dexamethasone / Generic mfg., levofloxacin / Generic mfg.
Trial completion, Surgery: LEADER7: Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery (clinicaltrials.gov) - Jun 11, 2019
P3, N=808, Completed, Sponsor: NTC srl
Recruiting --> Completed Recruiting --> Completed
- ||| levofloxacin / Generic mfg.
Trial completion, Surgery: iPERME: Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery (clinicaltrials.gov) - Jun 6, 2019
P2, N=125, Completed, Sponsor: NTC srl
Recruiting --> Completed Recruiting --> Completed
- | AzaSite (1% azithromycin ophthalmic solution) / Sun Pharma, Akorn, Nicox
Trial completion date: Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - May 28, 2019
P=N/A, N=20, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed Trial completion date: Jun 2019 --> Sep 2019
- | ceftriaxone / Generic mfg., levofloxacin / Generic mfg.
Trial completion date, Trial primary completion date: Antibiotics to Decrease Post ERCP Cholangitis (clinicaltrials.gov) - May 22, 2019
P4, N=200, Recruiting, Sponsor: University of Southern California
Trial completion date: Jun 2019 --> Sep 2019 Trial completion date: Feb 2019 --> Feb 2021 | Trial primary completion date: Feb 2019 --> Feb 2021